Fort Point Capital Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.9M Buy
7,549
+643
+9% +$138K 0.13% 78
2026
Q1
$1.5M Buy
6,906
+1,156
+20% +$256K 0.18% 79
2025
Q4
$1.25M Sell
5,750
-19
-0.3% -$4.33K 0.14% 91
2025
Q3
$1.34M Sell
5,769
-857
-13% -$175K 0.16% 90
2025
Q2
$1.23M Buy
6,626
+231
+4% +$42.9K 0.09% 133
2025
Q1
$1.34M Sell
6,395
-707
-10% -$137K 0.15% 102
2024
Q4
$1.26M Buy
7,102
+1,211
+21% +$223K 0.14% 107
2024
Q3
$1.16M Buy
5,891
+659
+13% +$123K 0.14% 98
2024
Q2
$897K Buy
5,232
+42
+0.8% +$6.96K 0.11% 129
2024
Q1
$945K Sell
5,190
-10
-0.2% -$1.72K 0.13% 126
2023
Q4
$806K Sell
5,200
-1,138
-18% -$166K 0.11% 121
2023
Q3
$945K Sell
6,338
-271
-4% -$39.8K 0.14% 93
2023
Q2
$890K Sell
6,609
-650
-9% -$95.3K 0.13% 105
2023
Q1
$1.16M Buy
7,259
+1,426
+24% +$218K 0.18% 94
2022
Q4
$943K Sell
5,833
-666
-10% -$102K 0.15% 105
2022
Q3
$872K Sell
6,499
-21
-0.3% -$3.01K 0.15% 108
2022
Q2
$999K Sell
6,520
-137
-2% -$20.9K 0.16% 99
2022
Q1
$1.08M Buy
6,657
+883
+15% +$128K 0.15% 101
2021
Q4
$782K Sell
5,774
-5
-0.1% -$591 0.11% 123
2021
Q3
$623K Buy
5,779
+2,344
+68% +$268K 0.09% 118
2021
Q2
$387K Buy
3,435
+100
+3% +$11.3K 0.07% 118
2021
Q1
$361K Buy
3,335
+8
+0.2% +$856 0.08% 116
2020
Q4
$356K Hold
3,327
0.08% 111
2020
Q3
$291K Sell
3,327
-69,007
-95% -$6.5M 0.07% 111
2020
Q2
$7.1M Buy
72,334
+177
+0.2% +$15.6K 2.22% 10
2020
Q1
$5.5M Sell
72,157
-7,850
-10% -$669K 2.36% 10
2019
Q4
$7.08M Buy
80,007
+1
+0% +$83 2.54% 9
2019
Q3
$6.06M Buy
80,006
+791
+1% +$54.2K 2.28% 10
2019
Q2
$5.76M Sell
79,215
-36,786
-32% -$2.89M 2.28% 9
2019
Q1
$9.35M Sell
116,001
-585
-0.5% -$47.9K 4.08% 6
2018
Q4
$10.7M Sell
116,586
-165
-0.1% -$14.5K 4.34% 6
2018
Q3
$11M Buy
116,751
+9
+0% +$853 3.33% 7
2018
Q2
$10.8M Buy
116,742
+458
+0.4% +$44.7K 3.63% 7
2018
Q1
$11M Sell
116,284
-160
-0.1% -$17.6K 4.03% 6
2017
Q4
$11.3M Buy
116,444
+1,023
+0.9% +$96.4K 5.25% 4
2017
Q3
$10.3M Buy
115,421
+1,903
+2% +$145K 4.91% 4
2017
Q2
$8.23M Hold
113,518
4.58% 5
2017
Q1
$7.4M Sell
113,518
-500
-0.4% -$31.4K 3.81% 6
2016
Q4
$6.95M Sell
114,018
-2,279
-2% -$139K 3.8% 6
2016
Q3
$7.33M Buy
116,297
+425
+0.4% +$27.5K 3.32% 8
2016
Q2
$7.17M Buy
115,872
+600
+0.5% +$36.6K 3.48% 7
2016
Q1
$6.58M Buy
115,272
+80
+0.1% +$4.46K 3.35% 7
2015
Q4
$6.82M Sell
115,192
-1,338
-1% -$77.1K 3.47% 6
2015
Q3
$6.34M Buy
116,530
+1,050
+0.9% +$68.3K 3.89% 6
2015
Q2
$7.76M Buy
+115,480
New +$7.54M 4.86% 4

Other funds holding ABBV

Fort Point Capital Partners's ABBV Position: Q2 2026 in Review

Fort Point Capital Partners increased its AbbVie (ABBV) stake by 9.3% in Q2 2026, buying an estimated $138K and bringing the position to 7,549 shares worth $1.9M. The position accounts for 0.13% of the portfolio, ranked #78.

Fort Point Capital Partners first reported a position in ABBV in Q2 2015 and has held it in 45 quarters since. The position peaked at $11.3M in Q4 2017. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Fort Point Capital Partners held 7,549 shares of AbbVie worth $1.9M as of Q2 2026.
  • Fort Point Capital Partners bought 643 AbbVie shares in Q2 2026, an estimated $138K.
  • AbbVie made up 0.13% of Fort Point Capital Partners's portfolio in Q2 2026, its #78 holding.
  • Fort Point Capital Partners first reported a position in AbbVie in Q2 2015 and has held it in 45 quarters since.
  • Fort Point Capital Partners's AbbVie position peaked at $11.3M in Q4 2017.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fort Point Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.